Tags

Type your tag names separated by a space and hit enter

The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.
Pharmacoepidemiol Drug Saf. 2008 Oct; 17(10):943-52.PD

Abstract

PURPOSE

To compare mortality and the incidence of hospitalization for myopathy, rhabdomyolysis, acute renal failure and acute liver injury in patients receiving rosuvastatin and those taking other statins.

METHODS

Patients prescribed a statin that they had not used before were selected from the UK General Practice Research Database (GPRD) and followed up from 1 April 2003 to 31 December 2005.

RESULTS

We studied 10 289 patients on rosuvastatin and 117 102 taking other statins. No cases of myopathy, rhabdomyolysis or acute liver injury occurred among rosuvastatin users. In those taking statins other than rosuvastatin, the incidence of myopathy was 0.4 (95% confidence interval (CI): 0.1-0.9), of rhabdomyolysis was 0.4 (95%CI: 0.1-0.9) and of acute liver injury was 0.4 (95%CI: 0.2-1.0), per 10 000 person-years. Fourteen cases of acute renal failure were identified (two among rosuvastatin users and 12 among other statin users). Among current users, the relative risk (RR) of acute renal failure in rosuvastatin users compared with other statin users was 1.16 (95%CI: 0.15-9.03).We identified 3232 deaths during the study period (173 in the rosuvastatin-treated group and 3059 in the other statin group). The RR of death associated with current use of rosuvastatin compared with other statins was 0.55 (95%CI: 0.44-0.68).

CONCLUSIONS

We found no evidence that patients prescribed rosuvastatin were at greater risk of these outcomes than patients prescribed other statins. There was no evidence of increased mortality among patients taking rosuvastatin, even after allowing for age, sex and prior statin use.

Authors+Show Affiliations

Spanish Centre for Pharmacoepidemiological Research (CEIFE), Madrid, Spain. lagarcia@ceife.esNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18425988

Citation

García-Rodríguez, Luis Alberto, et al. "The Safety of Rosuvastatin in Comparison With Other Statins in Over 100,000 Statin Users in UK Primary Care." Pharmacoepidemiology and Drug Safety, vol. 17, no. 10, 2008, pp. 943-52.
García-Rodríguez LA, Massó-González EL, Wallander MA, et al. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf. 2008;17(10):943-52.
García-Rodríguez, L. A., Massó-González, E. L., Wallander, M. A., & Johansson, S. (2008). The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiology and Drug Safety, 17(10), 943-52. https://doi.org/10.1002/pds.1603
García-Rodríguez LA, et al. The Safety of Rosuvastatin in Comparison With Other Statins in Over 100,000 Statin Users in UK Primary Care. Pharmacoepidemiol Drug Saf. 2008;17(10):943-52. PubMed PMID: 18425988.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. AU - García-Rodríguez,Luis Alberto, AU - Massó-González,Elvira Luján, AU - Wallander,Mari-Ann, AU - Johansson,Saga, PY - 2008/4/22/pubmed PY - 2009/5/5/medline PY - 2008/4/22/entrez SP - 943 EP - 52 JF - Pharmacoepidemiology and drug safety JO - Pharmacoepidemiol Drug Saf VL - 17 IS - 10 N2 - PURPOSE: To compare mortality and the incidence of hospitalization for myopathy, rhabdomyolysis, acute renal failure and acute liver injury in patients receiving rosuvastatin and those taking other statins. METHODS: Patients prescribed a statin that they had not used before were selected from the UK General Practice Research Database (GPRD) and followed up from 1 April 2003 to 31 December 2005. RESULTS: We studied 10 289 patients on rosuvastatin and 117 102 taking other statins. No cases of myopathy, rhabdomyolysis or acute liver injury occurred among rosuvastatin users. In those taking statins other than rosuvastatin, the incidence of myopathy was 0.4 (95% confidence interval (CI): 0.1-0.9), of rhabdomyolysis was 0.4 (95%CI: 0.1-0.9) and of acute liver injury was 0.4 (95%CI: 0.2-1.0), per 10 000 person-years. Fourteen cases of acute renal failure were identified (two among rosuvastatin users and 12 among other statin users). Among current users, the relative risk (RR) of acute renal failure in rosuvastatin users compared with other statin users was 1.16 (95%CI: 0.15-9.03).We identified 3232 deaths during the study period (173 in the rosuvastatin-treated group and 3059 in the other statin group). The RR of death associated with current use of rosuvastatin compared with other statins was 0.55 (95%CI: 0.44-0.68). CONCLUSIONS: We found no evidence that patients prescribed rosuvastatin were at greater risk of these outcomes than patients prescribed other statins. There was no evidence of increased mortality among patients taking rosuvastatin, even after allowing for age, sex and prior statin use. SN - 1099-1557 UR - https://www.unboundmedicine.com/medline/citation/18425988/The_safety_of_rosuvastatin_in_comparison_with_other_statins_in_over_100000_statin_users_in_UK_primary_care_ L2 - https://doi.org/10.1002/pds.1603 DB - PRIME DP - Unbound Medicine ER -